D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis

Thrombosis Research

Volumn 122, Issue 5, 2008, Pages 610-617

  Cosmi, Benilde ^a   Legnani, Cristina ^a   Cini, Michela ^a   Favaretto, Elisabetta ^a   Palareti, Gualtiero ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Hypercoagulability; Thrombophilia; Thrombosis; Venous thromboembolism; Vitamin K antagonists

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 8; D DIMER;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERCOAGULABILITY; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RISK FACTOR; THROMBOPHILIA; TREATMENT DURATION; VEIN OCCLUSION;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FACTOR VIII; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; VENOUS THROMBOSIS; VITAMIN K;

EID: 49549093366     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.12.024     Document Type: Article

References (31)

1. Hirsh J., and Lee A. How we diagnose and treat deep vein thrombosis. Blood 99 (2002) 3102-3110
2. Büller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., and Raskob G.E. Antithrombotic therapy for venous thromboembolic disease. Chest 126 (2004) 401S-428S
3. Hirsh J., Kearon C., and Ginsberg J. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med 157 (1997) 2174-2177
4. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 340 (1992) 873-876
5. Levine M.N., Hirsh J., Gent M., Turpie A.G., Weitz J., Ginsberg J., et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 74 (1995) 606-611
6. Schulman S., Rhedin A.S., Lindmarker P., Carlsson A., Larfars G., Nicol P., et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332 (1995) 1661-1665
7. Kearon C., Gent M., Hirsh J., Weitz J., Kovacs M.J., Anderson D.R., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340 (1999) 901-907
8. Linkins L.A., Choi P.O., and Douketis J.D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. Ann Intern Med 139 (2003) 893-900
9. Agnelli G., Prandoni P., Santamaria M.G., Bagatella P., Iorio A., Bazzan M., et al., Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345 (2001) 165-169
10. Agnelli G., Prandoni P., Becattini C., Silingardi M., Taliani M.R., Miccio M., et al., Warfarin Optimal Duration Italian Trial Investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 139 (2003) 19-25
11. Pinede L., Ninet J., Duhaut P., Chabaud S., Demolombe-Rague S., Durieu I., et al., Investigators of the "Duree Optimale du Traitement AntiVitamines K" (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf-vein thrombosis. Circulation 103 (2001) 2453-2460
12. Palareti G., Legnani C., Cosmi B., Guazzaloca G., Pancani C., and Coccheri S. Risk of venous thromboembolic recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 87 (2002) 7-12
13. Eichinger S., Minar E., Bialonczyk C., Hirschl M., Quehenberger P., Schneider B., et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 290 (2003) 1071-1074
14. Palareti G., Cosmi B., Legnani C., Tosetto A., Brusi C., Iorio A., et al., PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355 (2006) 1780-1789 [Erratum in: N Engl J Med. 2006; 355: 2797]
15. Bauer K.A. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 135 (2001) 367-373
16. Simioni P. Risk of recurrent venous thromboembolism and thrombophilia: does discrepancy make complexity and vice versa?. J Thromb Haemost 1 (2003) 16-18
17. Palareti G., Legnani C., Cosmi B., Valdre L., Lunghi B., Bernardi F., et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 108 (2003) 313-318
18. Piovella F., Crippa L., Barone M., Vigano D'Angelo S., Serafini S., Galli L., et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with DVT recurrence and new thrombosis. Haematologica 87 (2002) 515-522
19. Prandoni P., Lensing A.W., Prins M.H., Bernardi E., Marchiori A., Bagatella P., et al. Residual vein thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 137 (2002) 955-960
20. Cosmi B., Legnani C., Cini M., Guazzaloca G., and Palareti G. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Haemost 94 (2005) 969-974
21. Kraaijenhagen R.A., Anker P.S.I., Koopman M.M.W., Reitsma P.H., Prins M.H., van den Ende A., et al. High plasma concentration of factor VIII is a major risk factor for venous thromboembolism. Thromb Haemost 83 (2000) 5-9
22. Kyrle P.A., Minar E., Hirschl M., Bialonczyk C., Stain M., Schneider B., et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343 (2000) 457-462
23. Legnani C., Cosmi B., Cini M., Frascaro M., Guazzaloca G., and Palareti G. High plasma level of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 124 (2004) 504-510
24. Goldenberg N.A., Knapp-Clevenger R., Manco-Johnson M., and for the Mountain States Regional Thrombophilia Group. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 351 (2004) 1081-1088
25. Prandoni P., Cogo A., Bernardi E., Villalta S., Polistena P., Simioni P., et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation 88 (1993) 1730-1735
26. Fedullo P.F., and Tapson V.F. The evaluation of suspected pulmonary embolism. N Engl J Med 349 (2003) 1247-1256
27. Kearon C. Diagnosis of pulmonary embolism. CMAJ 168 (2003) 183-192
28. Shrivastava S., Ridker P.M., Glynn R.J., Goldhaber S.Z., Moll S., Bounameaux H., et al. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost 4 (2006) 1208-1214
29. O'Donnell J., Mumford A.D., Manning R.A., and Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 83 (2000) 10-13
30. Koster T., Blann A.D., Briet E., Vandenbroucke J.P., and Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345 (1995) 152-155
31. Kamphuisen P.W., Eikenboom J.C.J., and Bertina R.M. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 21 (2001) 731-738